Donate today and help reduce the rate of stillbirth in India and around the globe.
Donate today and help reduce the rate of stillbirth in India and around the globe.
Malaria is one of the world’s leading health problems, and particularly affects young children and pregnant women. While substantial progress has been made in reducing the global burden in the past decade, progress has stalled in recent years with a number of major challenges. There is an urgent need for effective vaccines, new drugs to treat the disease, new prevention strategies, and improvements in diagnosis and surveillance. Plasmodium falciparum, causes most clinical cases and deaths globally, however P. vivax also causes a high burden of disease in Asia and Pacific region.
Our research centres on five different approaches:
In addition, we apply our research to the Burnet Institute Healthy Mothers, Healthy Babies program in Papua New Guinea, which is a collaborative research program aimed at providing life-saving health care for women and children in PNG.
Burnet research, published in BMC Medicine, identifies waning immunity and previous exposure to malaria among children as challenges to overcome with global RTS,S malaria vaccine.
The global burden of malaria has increased, alongside the spread of drug-resistant infections. There is now a sense of urgency to develop more effective vaccines to combat the disease and accelerate towards elimination.
Collaboration will accelerate vaccine development for high-burden infectious diseases such as malaria.
On World Malaria Day, we’re affirming our commitment to a research program built on prevention, detection and treatment to accelerate the process of malaria elimination globally.
A new Burnet study reveals the role of specific proteins in the blood to prevent malaria in pregnancy, providing a potential new pathway for vaccine development.
A novel approach from Burnet scientists, targeting malaria as soon as it enters the bloodstream, has yielded exciting results towards the development of a much-needed vaccine.
Innovative new research led by Jo-Anne Chan and Michelle Boyle has linked the activation of immune cells to the induction of protective antibodies against malaria.
Professor James Beeson and colleagues warn about the impact of the COVID-19 pandemic on access to treatment and prevention of malaria.
Research led by Liriye Kurtovic has identified new ways to potentially enhance the effectiveness of malaria vaccine, RTS,S.
A major Burnet-led study has revealed a particular antibody type (called IgM) to be far more influential in combating malaria than previously understood.
New research led by Burnet has demonstrated the effective use of novel virus-like particles for malaria vaccines.
We made important discoveries about immune mechanisms generated by the malaria vaccine, RTS,S (Mosquirix, GSK), and why the vaccine is relatively short-lived, that could inform the future development of more effective and longer-lasting vaccines. Published in BMC Medicine.
We used novel approaches to explore the potential for a highly effective malaria vaccine. They identify important targets of functional antibodies and protective immunity and combinations of antigens that are associated with high levels of protective immunity, published in Nature Communications.
We defined the challenges and priorities required for the development of the next generation of malaria vaccines in a review published in the journal, Science Translational Medicine.
New research published in the Journal of Infectious Diseases has revealed important insights into malaria immunity in young children that could be used to inform the development of an effective malaria vaccine.
New research has revealed how antibodies produced by the immune system can recruit blood proteins known as complement to clear malaria to prevent infection. The findings open new strategies for malaria vaccines.
Burnet research team created a malaria ‘Frankenstein’ to reveal hidden secrets about Plasmodium vivax.
Image: Overview of malaria vaccine targets and strategies (from Beeson et al, Science Translational Medicine 2019)
Our aims are to identify the key targets of immunity, understand the mechanisms mediating immunity, and determine how immunity is acquired and maintained, for both P. falciparum and P. vivax). This involves combining detailed studies of immune responses with clinical and population studies of children and pregnant women in Africa, Asia and Papua New Guinea. Studies focus on understanding how antibodies prevent infection, neutralise and clear malaria parasites in the blood, and block malaria transmission. This includes and understanding the importance of interactions with monocytes, macrophages, neutrophils and other immune cells.
There is a strong need for effective vaccines to help achieve the long-term goal of malaria elimination. Our studies involve identifying and prioritising candidate antigens for vaccine development, determining the optimal formulation and delivery of vaccine antigens, and developing assays to measure vaccine-induced immune responses that can be used in vaccine development and clinical trials. Studies focus on several leading candidate antigens, and also aims to identify and characterise other antigens that could be developed as vaccines. We are also investigating vaccine approaches to induce potent protective immune responses, and evaluate immune responses in vaccine clinical trials.
Malaria infection commences following a mosquito bite when sporozoites enter the skin, migrate into the bloodstream and ultimately infect the liver. Blocking this initial infection is an important strategy in vaccine development, and we are identifying mechanisms and interactions involved in hepatocyte infection that could be targeted by vaccines. During blood-stage replication of Plasmodium, the merozoite form of the parasite (the form of the malaria parasite that invades red blood cells) infects red blood cells and develops and replicates inside them. This is an essential step in the Plasmodium life-cycle that could be targeted by vaccines and novel drugs. Identifying molecular and cellular interactions involved in invasion of red blood cells by P. falciparum merozoites using novel approaches we have recently developed. We will use this knowledge to complement our research on vaccine development and drug discovery.
Additional tools are required to facilitate the identification of hot-spots of malaria transmission and identify population groups with higher transmission for targeted malaria interventions to accelerate progress in malaria elimination. As we move from malaria control to elimination, accompanied by declining malaria transmission, the prevalence of active infection is greatly reduced, and low-density infections that are not detected by current diagnostic tests become more common. This presents a significant practical and financial challenge to identifying malaria transmission hot-spots and populations with active or recent infection. A further problem is access and resources. Many high-risk populations live in rural and remote locations with limited infrastructure and access. We are investigating surveillance strategies for malaria, including the use of serology to detect recent malaria exposure and community-based strategies for surveillance. We are working on the development and evaluation of simple low-cost rapid surveillance tools for use by field surveillance teams or by community-based health care workers that would facilitate surveillance, estimating malaria burden, and reporting, and enable better planning of interventions and services.
Our work aims to understand the negative consequences of malaria and determine strategies for prevention, particularly in pregnant women and young children. This will assist with the understanding of how malaria interacts with other health problems, such as anaemia and other infections, to worsen health outcomes in children and pregnant women. In addition, we conduct operational research to provide insights into how health services can be modified or strengthened to improve access and effective treatment and prevention of malaria and other illnesses.
Our group is a member of the Australian Centre for Excellence in Malaria Elimination (ACREME).